Crolom®
cromolyn 4.0% · ophthalmic solution
Allergy
Approved uses
Vernal keratoconjunctivitis, including vernal conjunctivitis and vernal keratitis
1 or 2 drops in each eye 4 to 6 times daily at regular intervals
OFF-LABELNot in the FDA label for this product
Seasonal allergic conjunctivitis
1 or 2 drops in each eye 4 to 6 times daily, the labeled regimen; seasonal trials of 4% cromoglycate dosed QID
Cochrane · class, short-term
Cochrane review of 30 randomized trials and 4344 participants concluded that topical antihistamines and mast cell stabilizers as a class, sodium cromoglycate among the drugs evaluated, reduce symptoms and signs of seasonal allergic conjunctivitis versus placebo in the short term, with no long term efficacy data and highly variable reporting quality. A comparative review of the seasonal trials notes that cromoglycate eye drops did not control breakthrough symptoms during peak pollen challenge.
Contraindications
Hypersensitivity to cromolyn sodium or to any of the other ingredients in the formulation.
Ophthalmic solution, cromolyn sodium 40 mg/mL (4%), 10 mL opaque polyethylene bottle with controlled dropper tip
Mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells that occurs after exposure to specific antigens, and it acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. It has no intrinsic vasoconstrictor, antihistamine, or anti-inflammatory activity.
Warnings & Precautions
- Administration at regular intervals: Patients should be advised that the effect of therapy is dependent upon its administration at regular intervals, as directed; symptomatic response is usually evident within a few days, but longer treatment for up to six weeks is sometimes required.
- Contact lens wear: Do not wear contact lenses during treatment; users of contact lenses should refrain from wearing lenses while exhibiting the signs and symptoms of vernal keratoconjunctivitis, vernal conjunctivitis, or vernal keratitis.
- Dosing frequency: The recommended frequency should not be exceeded.
- Transient stinging or burning: Patients may experience a transient stinging or burning sensation following application.
- Do not use with other ocular medication: Do not use with any other ocular medication unless directed by your physician.
- Contamination: To avoid contamination, do not touch dropper tip to the eye, fingers, or any other surface; replace cap after use.
Common Side Effects
Transient ocular stinging or burning upon instillation is the most frequently reported adverse reaction attributed to cromolyn sodium, on the basis of reoccurrence following readministration. Conjunctival injection, watery eyes, itchy eyes, dryness around the eye, puffy eyes, eye irritation, and styes have been reported as infrequent events, and it is unclear whether they are attributed to the drug. Immediate hypersensitivity reactions have been reported rarely and include dyspnea, edema, and rash.
Pregnancy: Category B. No adequate and well controlled studies in pregnant women; subcutaneous and intravenous animal doses 35 to 205 times the maximum daily human dose on a mg/m2 basis produced no fetal malformation, and increased resorption and decreased fetal weight appeared only at parenteral doses high enough to produce maternal toxicity. Because animal reproduction studies are not always predictive of human response, use during pregnancy only if clearly needed.
Lactation: Excretion in human milk is unknown; use caution in nursing women.
Safety and effectiveness below age 4 not established.